glp-1 discontinuation weight regain Many Patients Maintain Loss a Year After Stopping Semaglutide and Liraglutide Fractyl Health Reports Positive 6-Month

Conclusions In summary, this study addresses the common and challenging clinical problem of radiation-induced proctitis

Presented for research literature review only Benveniste R et al

The FDA has acknowledged this reality on the label itself: weight care requires ongoing therapy , and GLP-1 drugs are approved for chronic weight management only as an adjunct to diet and exercise they are not magic bullets that cure obesity after a few doses

Across the full GLP-1 and obesity drug space, the post-2026 picture is a price-expansion wave led by Indian and Chinese biosimilars and by new dual or triple-agonist molecules, yet real uptake in the USA and EU will be shaped less by tariffs and more by regulatory timing, drug-device parity on pens and human-factors equivalence for AB-substitution, secondary IP and Orange Book hurdles, and payer or formulary contracting

doi: 10.1016/j.cmet.2022.07.013 66 BossartMWagnerMElvertREversAHbschleTKloeckenerTet al

As NADH is metabolized by complex I a reduction in the production in NADH will result in a relative deficit in complex I, consistent with the findings from the ETC muscle studies